Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Sells $730,450.00 in Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 17,500 shares of the firm’s stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $41.74, for a total transaction of $730,450.00. Following the completion of the sale, the chief executive officer now directly owns 143,603 shares of the company’s stock, valued at approximately $5,993,989.22. The trade was a 10.86 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Marshall Fordyce also recently made the following trade(s):

• On Wednesday, December 18th, Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock. The shares were sold at an average price of $43.07, for a total transaction of $753,725.00.
• On Wednesday, December 11th, Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock. The stock was sold at an average price of $46.94, for a total transaction of $821,450.00.
• On Wednesday, October 23rd, Marshall Fordyce sold 19,375 shares of Vera Therapeutics stock. The shares were sold at an average price of $40.39, for a total value of $782,556.25.

Vera Therapeutics Stock Down 12.3 %

VERA stock traded down $5.17 on Friday, hitting $37.02. 940,406 shares of the company’s stock were exchanged, compared to its average volume of 513,118. The firm has a 50 day moving average price of $45.55 and a two-hundred day moving average price of $40.95. Vera Therapeutics, Inc. has a 12-month low of $14.20 and a 12-month high of $51.61. The stock has a market cap of $2.34 billion, a P/E ratio of -14.18 and a beta of 1.15. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.21). As a group, equities research analysts expect that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on VERA shares. Guggenheim upped their target price on Vera Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a report on Monday, October 28th. Wedbush increased their target price on shares of Vera Therapeutics from $30.00 to $38.00 and gave the stock a “neutral” rating in a report on Friday, November 8th. Wells Fargo & Company started coverage on shares of Vera Therapeutics in a research report on Thursday, November 21st. They issued an “overweight” rating and a $70.00 price target for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $107.00 price objective on shares of Vera Therapeutics in a report on Tuesday, October 1st. Finally, Evercore ISI upgraded Vera Therapeutics to a “strong-buy” rating in a report on Monday, September 16th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $63.50.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp grew its holdings in shares of Vera Therapeutics by 6.3% during the second quarter. Bank of New York Mellon Corp now owns 165,322 shares of the company’s stock valued at $5,981,000 after buying an additional 9,854 shares during the last quarter. TD Asset Management Inc increased its holdings in shares of Vera Therapeutics by 18.4% in the second quarter. TD Asset Management Inc now owns 154,338 shares of the company’s stock valued at $5,584,000 after purchasing an additional 24,000 shares during the period. Victory Capital Management Inc. raised its stake in shares of Vera Therapeutics by 202.4% in the second quarter. Victory Capital Management Inc. now owns 33,707 shares of the company’s stock worth $1,220,000 after purchasing an additional 22,560 shares during the last quarter. Arizona State Retirement System lifted its holdings in shares of Vera Therapeutics by 14.4% during the second quarter. Arizona State Retirement System now owns 9,907 shares of the company’s stock worth $358,000 after purchasing an additional 1,250 shares during the period. Finally, American Century Companies Inc. purchased a new stake in Vera Therapeutics in the second quarter valued at approximately $14,015,000. Institutional investors and hedge funds own 99.21% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.